Xenon Pharmaceuticals Inc. (XENE)
收市後：
| 前收市價 | 39.04 |
| 開市 | 39.16 |
| 買盤 | 37.98 x 200 |
| 賣出價 | 38.19 x 100 |
| 今日波幅 | 37.53 - 39.70 |
| 52 週波幅 | 27.99 - 50.99 |
| 成交量 | |
| 平均成交量 | 341,006 |
| 市值 | 2.873B |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.72 |
| 業績公佈日 | 2024年8月07日 - 2024年8月12日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 58.32 |
Insider MonkeyHedge Funds are Racking Up Shares of This Healthcare Stock
We recently compiled a list of the 7 Best Mid-Cap Healthcare Stocks To Buy Now and in this article we will look at whether hedge funds like Xenon Pharmaceuticals Inc. (NASDAQ:XENE). Challenges in the Health Sector The healthcare industry is considered to be a fairly defensive sector due to its need. According to a World […]
Insider MonkeyXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2024 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2024 Earnings Call Transcript May 9, 2024 Xenon Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.61771, expectations were $-0.69. Xenon Pharmaceuticals Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing […]
ZacksXenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.
